Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
An institutional-grade, numbers-driven thesis on BRVE — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates Braveheart Bio, Inc. (BRVE) 52/100 with a 12-month base-case forecast of $32.28 — +7.6% versus the current price of $30.00. Braveheart Bio, Inc. trades at $30.00 in the Healthcare sector, with a market capitalisation of $2.12B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for BRVE is $32.28, implying +7.6% versus the current price. The model's 12-month scenario range runs from $27.87 (bear) to $38.43 (bull), with a base case of $32.28.
BRVE currently carries a TradersQuant composite score of 52/100, which we read as a neutral-to-watch signal. Our 12-month price target of $32.28 implies +7.6% from $30.00. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for BRVE is $32.28, about +7.6% versus the latest price of $30.00.
TradersQuant's 12-month model forecast for BRVE is a base case of $32.28, ranging from $27.87 (bear) to $38.43 (bull), an expected return of +7.6%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for BRVE over the next 12 months is $32.28 in the base case (bear $27.87, bull $38.43), versus today's price of $30.00. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for BRVE — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates BRVE's fair value at $37.80, implying +26.0% of expected upside versus the current price.
Braveheart Bio does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
